Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease
Tuesday, May 7, 2024
Live Virtual Meeting
6:30 PM – 7:30 PM ET
Tuesday, May 7, 2024
Live Virtual Meeting
6:30 PM – 7:30 PM ET
The Pennsylvania Society of Oncology and Hematology cordially invites you to attend a CME/CPE/CE-certified live webinar titled, “Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease.” This activity will improve the knowledge, confidence, and competence of learners in risk assessment and individualizing therapy for HR-positive/HER2-negative high-risk breast cancer.
Scan QR Code to Register.
FACULTY
Laura M. Spring, MD
Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts
For full accreditation information and to register, click here or go to: www.clinicaloptions.com/BreastHRPosLLCH
Agenda
Target Audience: This program is intended for medical oncologists, pharmacists, nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients with breast cancer.
Learning Objectives:
Upon completion of this activity, learners should be able to:
Accreditation Statements
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-045-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.
Disclosures will be made known to learners before the activity.
Scan QR Code to Register.
FACULTY
Laura M. Spring, MD
Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts
For full accreditation information and to register, click here or go to: www.clinicaloptions.com/BreastHRPosLLCH
Agenda
- Risk Assessment in HR-Positive/HER2-Negative Breast Cancer
- Individualizing Therapy for High-Risk HR-Positive/HER2-Negative Early Breast Cancer
- Individualizing Therapy for High-Risk HR-Positive/HER2-Negative Metastatic Breast Cancer
- Strategies for Promoting Adherence and Persistence to Therapies in Patients With High-Risk Breast Cancer
Target Audience: This program is intended for medical oncologists, pharmacists, nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients with breast cancer.
Learning Objectives:
Upon completion of this activity, learners should be able to:
- Assess risk in patients with HR+/HER2- EBC and MBC to guide optimal therapy selection for patients with high-risk features to improve clinical outcomes
- Select individualized adjuvant therapies for patients with high-risk HR+/HER2- EBC based on tumor characteristics, predictive biomarkers, the latest clinical data, approvals, guidelines, and expert recommendations
- Plan an individualized sequence of therapies for patients with high-risk HR+/HER2- MBC based on risk assessment, the latest clinical data, approvals, guidelines, and expert recommendations
- Implement evidence-based management of adverse events associated with CDK4/6 inhibitors for high-risk HR+/HER2- breast cancer
- Promote adherence to oral targeted therapies in patients with HR+/HER2- breast cancer
Accreditation Statements
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-045-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.
Disclosures will be made known to learners before the activity.
Provided by Clinical Care Options, LLC
This activity is supported by an educational grant from Lilly.
This activity is supported by an educational grant from Lilly.